BioSpace News Archive

Natera, Inc. today reported preliminary results for the quarter ended June 30, 2021 for volume and revenue growth.

Anika Therapeutics, Inc. today announced that the Company plans to issue its second quarter 2021 financial results after the close of the market on Thursday, August 5, 2021 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

Anthos Therapeutics, a clinical-stage biopharma company developing innovative therapies for cardiovascular and metabolic diseases, today announced final results from the Phase 2 ANT-005 study with its novel investigational anticoagulant abelacimab

BioMarin Pharmaceutical Inc. today announced new data for valoctocogene roxaparvovec in its positive pivotal study, GENEr8-1, during an oral presentation at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress.

Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2021 of $1.06 per share on the company’s common stock.

The Government of Canada is prioritizing the health and safety of everyone in Canada by taking a risk-based and measured approach to re-opening our borders.

Japanese pharmaceutical manufacture Nippon Chemiphar Co., LTD is developing a novel, first-in-its-class prescription cough medicine that has the potential to become the second new Rx cough product in roughly 70 years.

Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology leader delivering on its vision for more flexible and accessible dialysis care, today announced that John E. Milad, Chief Executive Officer, will present a corporate overview at the Private Healthcare Company Virtual Summer Symposium, hosted by LifeSci Partners, on July 21-23, 2021.

Immunic, Inc. (the “Company”) (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the closing of an underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $10.00 per share.